Experience
Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd.
Mylan Pharmaceuticals Inc.
Bausch Health Ireland Ltd.
Represented Bausch Health et al. in Abbreviated New Drug Application (ANDA) litigation and related inter partes reviews (IPRs) involving Trulance® (plecanatide) tablets for the treatment of irritable bowel syndrome and chronic idiopathic constipation, leading to a final decision confirming patentability in the first IPR proceeding and non-institution decisions in the remaining four IPR proceedings and a favorable settlement post-trial.
Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd., IPR2022-00722, -01102, -01103, -01104, -01105, IPR2023-00016, PTAB, Judges Hardman, Hulse, Sheridan, Valek
Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd., 26-1595, Fed. Cir.
Bausch Health Ireland Ltd. v. Mylan Pharmaceuticals Inc., 1:21-cv-00611, D. Del., Judge Stark
Bausch Health Ireland Ltd. v. Mylan Pharmaceuticals Inc., 2:21-cv-10057, -10403, 2:23-cv-00170, -03333, 2:24-cv-07182, -11179, D.N.J., Judge Chesler
Bausch Health Ireland Ltd. v. Mylan Pharmaceuticals Inc., 2:21-cv-00573, W.D. Pa., Judge Cercone, Hardy
Bausch Health Ireland Ltd. v. Mylan Pharmaceuticals Inc., 1:22-cv-00020, -00085, 1:24-cv-00036, 1:25-cv-00003, N.D.W. Va., Kleeh
